A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 6, 2013, Pages 3407-3413

  Martin, Christine M A ^a   Irwin, Nigel ^a   Flatt, Peter R ^a   Gault, Victor A ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Acylation; Analogue; Glucose tolerance; Glucose dependent insulinotropic polypeptide (GIP); Insulin secretion; Type 2 diabetes

Indexed keywords

(DEXTRO ALANINE 2)GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; (DEXTRO ALANINE 2)GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE[LYSINE 37 PALMITATE FATTY ACID]; ANTIDIABETIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCOSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BODY FAT; BODY WEIGHT; CALORIC INTAKE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC LOAD; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BODY FAT DISTRIBUTION; DIABETES MELLITUS, EXPERIMENTAL; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL AGENTS; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE;

MUS;

EID: 84875989116     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.03.011     Document Type: Article

References (29)

1. N. Irwin, and P.R. Flatt Therapeutic potential for GIP receptor agonists and antagonists Best Pract Res Clin Endocrinol Metab 23 2009 499 512
2. J.J. Meier, M.A. Nauck, D. Kranz, J.J. Holst, C.F. Deacon, D. Gaeckler, W.E. Schmidt, and B. Gallwitz Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects Diabetes 53 53 2004 654 662
3. V.A. Gault, F.P. O'Harte, and P.R. Flatt Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 37 2003 253 263
4. 2]glucose- dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats Diabetes 51 2002 652 661
5. S.B. Widenmaier, S.J. Kim, G.K. Yang, T. De Los Reyes, C. Nian, A. Asadi, Y. Seino, T.J. Kieffer, Y.N. Kwok, and C.H.S. McIntosh A GIP receptor agonist exhibits β-cell anti-apoptotic actions in rat models of diabetes resulting in improved β-cell function and glycemic control PLoS One 5 2010 e9590
6. V.A. Gault, D.W. Porter, N. Irwin, and P.R. Flatt Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high fat fed mice J Endocrinol 208 2011 265 271
7. 37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential J Med Chem 49 2006 1047 1054
8. N. Irwin, G.C. Clarke, B.D. Green, B. Greer, P. Harriott, V.A. Gault, F.P. O'Harte, and P.R. Flatt Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide Biochem Pharmacol 72 2006 719 728
9. 37) Biol Chem 386 2005 679 687
10. N. Irwin, B.D. Green, V.A. Gault, B. Greer, P. Harriott, C.J. Bailey, P.R. Flatt, and F.P. O'Harte Degradation, insulin secretion and antihyperglycemic actions of two palmitate-derivatized N-terminal proglutamyl analogues of glucose dependent insulinotropic polypeptide J Med Chem 48 2005 1244 1250
11. N. Irwin, B.D. Green, M.H. Mooney, B. Greer, P. Hariott, C.J. Bailey, V.A. Gault, F.P. O'Harte, and P.R. Flatt A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes J Pharmacol Exp Ther 314 2005 1187 1194
12. J.A. Loveshin, and D.J. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat Rev Endocrinol 5 2009 262 269
13. 13)GIP Cell Biol Int 27 2003 41 46
14. N.H. McClenaghan, C.R. Barnett, E. Ah-Sing, Y.H. Abdel-Wahab, F.P. O'Harte, T.W. Yoon, S.K. Swanston-Flatt, and P.R. Flatt Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion Diabetes 45 1996 1132 1140
15. P.R. Flatt, and C.J. Bailey Abnormal plasma glucose and insulin responses in heterozygous lean(ob/+) mice Diabetologia 20 1981 573 577
16. P.L. McClean, N. Irwin, R.S. Cassidy, J.J. Holst, V.A. Gault, and P.R. Flatt GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet Am J Physiol Endocrinol Metab 293 2007 1746 1755
17. M.A. Nauck, E. Bartels, C. Orskov, R. Ebert, and W. Creutzfeldt Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations J Clin Endocrinol Metab 76 1993 912 917
18. L.L. Kjems, J.J. Holst, A. Vølund, and S. Madsbad The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects Diabetes 52 2003 380 386
19. W.K. Ward, D.C. Bolgiano, B. McKnight, J.B. Halter, and D. Porte Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus J Clin Invest 74 1984 1318 1328
20. M.A. Nauck, A. El-Ouaghlidi, B. Gabrys, K. Hücking, J.J. Holst, C.F. Deacon, B. Gallwitz, W.E. Schmidt, and J.J. Meier Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes Regul Pept 122 2004 209 217
21. J.J. Meier, M.A. Nauck, N. Siepmann, M. Greulich, J.J. Holst, C.F. Deacon, W.E. Schmidt, and B. Gallwitz Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects Metabolism 52 2003 1579 1585
22. K. Aaboe, F.K. Knop, T. Vilsboll, A. Vølund, U. Simonsen, C.F. Deacon, S. Madsbad, J.J. Holst, and T. Krarup KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes J Clin Endocrinol Metab 94 2009 603 608
23. P.V. Højberg, T. Vilsbøll, R. Rabøl, F.K. Knop, M. Bache, T. Krarup, J.J. Holst, and S. Madsbad Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes Diabetologia 52 2009 199 207
24. J.P. Fortin, D. Chinnapen, M. Beinborn, W. Lencer, and A.S. Kopin Discovery of dual-action membrane-anchored modulators of incretin receptors PLoS One 6 2011 e24693
25. D.W. Porter, N. Irwin, P.R. Flatt, Holscher, and V.A. Gault Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high fat fed mice Eur J Pharmacol 650 2011 688 693
26. N. Irwin, and P.R. Flatt Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications Diabetologia 52 2009 1724 1731
27. B.D. Kerr, N. Irwin, F.P. O'Harte, C.J. Bailey, P.R. Flatt, and V.A. Gault Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties Biochem Pharmacol 78 2009 1008 1016
28. S.J. Kim, C. Nian, S. Karunakaran, S.M. Clee, C.M. Isales, and C.H.S. McIntosh GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis PLoS One 7 2012 e40156
29. S. Piteau, A. Olver, S.J. Kim, K. Winter, J.A. Pospisilik, F. Lynn, S. Manhart, H.U. Demuth, M. Speck, R.A. Pederson, and C.H. McIntosh Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat Biochem Biophys Res Commun 362 2007 1007 1012